Monte Rosa TherapeuticsGLUE
GLUE
About: Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Employees: 134
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more call options, than puts
Call options by funds: $413K | Put options by funds: $206K
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
1% more funds holding
Funds holding: 104 [Q4 2024] → 105 (+1) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
2.49% less ownership
Funds ownership: 99.26% [Q4 2024] → 96.77% (-2.49%) [Q1 2025]
35% less capital invested
Capital invested by funds: $423M [Q4 2024] → $276M (-$147M) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 44
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
104%
upside
Avg. target
$13.50
175%
upside
High target
$17
246%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Wells Fargo Derek Archila | 104%upside $10 | Equal-Weight Maintained | 21 Mar 2025 |
Wedbush Robert Driscoll | 246%upside $17 | Outperform Maintained | 21 Mar 2025 |
Financial journalist opinion
Based on 3 articles about GLUE published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inf
Positive
Zacks Investment Research
6 days ago
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
2 weeks ago
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m.
Positive
Zacks Investment Research
1 month ago
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical response in heavily pretreated castration-resistant prostate cancer patients resistant to AR therapy; additional results expected in H2 2025 MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Cyclin E1 (CCNE1) and CDK2-directed MGD programs for the treatment of CCNE1-driven solid tumors and ER+ breast cancer advancing toward the clinic; IND submission anticipated in 2026 Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter ended March 31, 2025. “We've made significant progress across our entire portfolio in the development of our only-in-class and first-in-class molecular glue degrader therapeutics, targeting diseases poorly addressed by conventional pharmaceutical approaches,” said Markus Warmuth, M.D.
Neutral
GlobeNewsWire
1 month ago
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader, MRT-51443, to treat HR-positive/HER2-negative breast cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, IL. “In preclinical models of HR-positive/HER2-negative breast cancer, the combination of MRT-51443 with a CDK4/6 inhibitor and anti-estrogen therapy drove robust tumor regressions, demonstrating notably deeper tumor responses than the standard of care combination alone,” said Sharon Townson, Ph.D.
Neutral
Seeking Alpha
2 months ago
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Participants Kelly Shi - Jefferies Edward Tenthoff - Piper Sandler Mark Fromm - TD Cowen Robert Driscoll - Wedbush Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Operator Greetings, and welcome to Monte Rosa Therapeutics Conference Call to discuss the company's pipeline updates and clinical results. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
2 months ago
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; deprioritizing further expansion arms in SCLC, NSCLC and NE tumors MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025 Strong cash position expected to fund operations into 2028 through multiple anticipated proof-of-concept clinical readouts Company to host conference call and webcast today at 8:00 a.m. ET BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported a clinical update, business highlights, and financial results for the fourth quarter ended December 31, 2024.
Neutral
GlobeNewsWire
3 months ago
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will present a pipeline update including clinical results from its Phase 1 SAD/MAD study of the VAV1-directed MGD MRT-6160 and its Phase 1/2 study of MRT-2359 in MYC-driven solid tumors.
Charts implemented using Lightweight Charts™